Mhedzisiro Inovimbisa yeKurapa kweCD7 CAR-T muKurapa Relapsed/Refractory Peripheral T-Cell Lymphoma paASH 2024
PaMusangano weGore negore wechi66 weAmerican Society of Hematology (ASH) 2024, wakaitwa kubva musi wa7 kusvika 10 Zvita muSan Diego, Prof. Lu Peihua vekuLu Daopei Hospital vakapa bvunzo yekiriniki yePhase I yekurapa kweCD7-targeted Chimeric Antigen Receptor T-cell (CAR-T) therapy yekurapa peripheral yakadzoserwa/inorapwa. T-Cell Lymphoma (R/R PTCL). Uku kufambira mberi kwakakosha mukurapa kenza yeT-cell, uko nzira dzekurapa dziripo dzave shoma uye kazhinji dzisingashande zvakanaka.
R/R PTCL inozivikanwa nekutadza kwayo kurapwa, kunyanya muvarwere vakamborapwa nenzira dzakasiyana-siyana, kusanganisira allogeneic hematopoietic hematopoietic stem cell transplantation (allo-HSCT). Pasinei neizvi, CD7 CAR-T therapy, kunyanya NS7CAR-T cell therapy yakagadzirwa nechikwata chaProf. Lu, yakaratidza mhedzisiro inokurudzira mukurapa varwere vane CD7-positive R/R PTCL. Mukuyedzwa uku, varwere vashanu, vane makore ari pakati pe39 ne60, vane matanho epamusoro eR/R PTCL vakanyoreswa pakati paKubvumbi 2021 naMbudzi 2023. Varwere ava vakamborapwa nzira nhanhatu dzekare, kusanganisira mumwe munhu ane nhoroondo yekutapurirwa kwemasero emuviri.
Mhedzisiro yacho yaivimbisa: mukati menguva yekutevera yemazuva 234, 60% yevarwere vakawana remission yakakwana (CR), uye murwere mumwe chete akawana remission isina chikamu (PR). Chinokosha ndechekuti kurapwa kwakaratidza huwandu hwakanyanya hwekuwanda kwemasero eCAR-T uye kuramba kuripo muvarwere, nepakati pehuwandu hwemasero eCAR-T anosvika 93.5% kushanda zvakanaka. Zvakakosha kuti, pakanga pasina migumisiro yakaipa yakadai se neurotoxicity, uye cytokine release syndrome (CRS) yakanga isina kusimba, murwere mumwe chete achiwana CRS yegiredhi rechipiri. Kuchengetedzwa kwacho kwaikwanisika, pasina chepfu dzakanyanya dzakaonekwa.
Tsvagiridzo yaProf. Lu inoratidza kugona kwekurapa kweCD7 CAR-T senzira yekuchinja zvinhu mukurapa kenza dzeT-cell, kunyanya kuvarwere vane sarudzo shoma dzekurapa kana kuti vasina. Pamusoro pemhedzisiro yakanaka muPTCL, timu yaProf. Lu yakambowana kushanda kwakanaka mukurapa T-cell acute lymphoblastic leukemia (T-ALL) uye T-cell lymphoblastic lymphoma (T-LBL), ine chiyero chekuregererwa kwemasero chinosvika 95% muboka revarwere makumi matanhatu. Zvichitevera mhedzisiro iyi, timu iyi iri kuwedzera tsvagiridzo yayo mune dzimwe kenza dzeropa dzakadai seacute myeloid leukemia (AML), nedata rekutanga richiratidza chiyero chekuregererwa kwemasero che70% muvarwere vane CD7-positive AML.
Pasinei nemigumisiro iyi yakanaka, Purofesa Lu anosimbisa kukosha kwekubatanidza kurapwa kweCD7 CAR-T ne allo-HSCT kuti pave nemhedzisiro yenguva refu. Kusiyana kwezvirwere zveT-cell kunoda nzira yakakwana yekurapa kuti pave nemikana yekuregererwa kwenguva refu uye kurapwa kunogona kuitika. Chikwata ichi chinoramba chichivandudza nzira yavo uye kuwedzera zviratidzo zvekurapa kweCD7 CAR-T therapy.
Basa guru raProf. Lu, iro rakatorapa varwere vanopfuura mazana matatu neCD7 CAR-T therapy, rinomiririra danho guru rekufambira mberi mukurapa kenza yeT-cell. Tichienderera mberi, timu iyi yakazvipira kuwedzera miedzo yekiriniki uye kunatsiridza matekiniki ekurapa CAR-T cell, ichiva nechokwadi chekuti varwere vakawanda vachabatsirwa nenzira iyi itsva.
Kuedzwa uku kwePhase I kunovimbisa paASH 2024 kunoratidza kugona kwekurapa kweCD7 CAR-T senzira itsva mukurapa kwekenza yeropa, zvichipa tariro kuvarwere vane zvirwere zvaisamborapika.